Advertisement

Use of HIV pre-exposure prophylaxis during the preconception, antepartum and postpartum periods at two United States medical centers

      Background

      Pregnancy may increase a woman’s susceptibility to HIV. Maternal HIV acquisition during pregnancy and lactation is associated with increased perinatal and lactational HIV transmission. There are no published reports of preexposure prophylaxis use after the first trimester of pregnancy or during lactation.

      Objective

      The purpose of this study was to report the use of preexposure prophylaxis and to identify gaps in HIV prevention services for women who were at substantial risk of HIV preconception and during pregnancy and lactation at 2 United States medical centers.

      Study Design

      Chart review was performed on women who were identified as “at significant risk” for HIV acquisition preconception (women desiring pregnancy) and during pregnancy and lactation at 2 medical centers in San Francisco and New York from 2010-2015. Women were referred to specialty clinics for women who were living with or were at substantial risk of HIV.

      Results

      Twenty-seven women who were identified had a median age of 27 years. One-half of the women had unstable housing, 22% of the women had ongoing intimate partner violence, and 22% of the women had active substance use. Twenty-six women had a male partner living with HIV, and 1 woman had a male partner who had sex with men. Of the partners who were living with HIV, 73% (19/26) were receiving antiretroviral therapy, and 42% (11/26) had documented viral suppression. Thirty-nine percent (10/26) of partners had known detectable virus, and 19% (5/26) had unknown viral loads. Women were identified by clinicians, health educators, and health departments. Approximately one-third of the women were identified preconception (8/27); the majority of the women were identified during pregnancy (18/27) with a median gestational age of 20 weeks (interquartile range, 11–23), and 1 woman was identified in the postpartum period. None of the pregnant referrals had received safer conception counseling to reduce HIV transmission. Twenty-six percent of all women (7/27) were eligible for postexposure prophylaxis at referral, of whom 57% (4/7) were offered postexposure prophylaxis. In 30% (8/27), the last HIV exposure was not assessed and postexposure prophylaxis was not offered. The median time from identification as “at substantial risk” to consultation was 30 days (interquartile range, 2–62). Two women were lost to follow up before consultation. One woman who was identified as “at significant risk” was not referred because of multiple pregnancy complications. She remained in obstetrics care and was HIV-negative at delivery but was lost to follow up until 10 months after delivery when she was diagnosed with HIV. No other seroconversions were identified. Of referrals who presented and were offered preexposure prophylaxis, 67% women (16/24) chose to take it, which was relatively consistent whether the women were preconception (5/8), pregnant (10/15), or after delivery (1/1). Median length of time on preexposure prophylaxis was 30 weeks (interquartile range, 20–53). One-half of women (10/20) who were in care at delivery did not attend a postpartum visit.

      Conclusion

      Women at 2 United States centers frequently chose to use preexposure prophylaxis for HIV prevention when it was offered preconception and during pregnancy and lactation. Further research and education are needed to close critical gaps in screening for women who are at risk of HIV for pre- and postexposure prophylaxis eligibility and gaps in care linkage before and during pregnancy and lactation. Postpartum women are particularly vulnerable to loss-to-follow-up and miss opportunities for safe and effective HIV prevention.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva 2015. Available at: http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1. Accessed February 1, 2016.

      2. Centers for Disease Control and Prevention. Pre-exposure prophylaxis for the prevention of HIV infection in the United States—2014: a clinical practice guideline. Atlanta, GA 2014. Available at: http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. Accessed February 1, 2016.

        • Smith D.K.
        • Van Handel M.
        • Wolitski R.J.
        • et al.
        Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition - United States, 2015.
        MMWR Morb Mortal Wkly Rep. 2015; 64: 1291-1295
        • Drake A.L.
        • Wagner A.
        • Richardson B.
        • John-Stewart G.
        Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis.
        PLoS Me. 2014; 11: e1001608
        • Sheffield J.S.
        • Wendel Jr., G.D.
        • McIntire D.D.
        • Norgard M.V.
        The effect of progesterone levels and pregnancy on HIV-1 coreceptor expression.
        Reprod Sci. 2009; 16: 20-31
        • Birkhead G.S.
        • Pulver W.P.
        • Warren B.L.
        • Hackel S.
        • Rodriguez D.
        • Smith L.
        Acquiring human immunodeficiency virus during pregnancy and mother-to-child transmission in New York: 2002-2006.
        Obstet Gynecol. 2010; 115: 1247-1255
        • Humphrey J.H.
        • Marinda E.
        • Mutasa K.
        • et al.
        Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study.
        BMJ. 2010; 341: c6580
        • Nesheim S.
        • Harris L.F.
        • Lampe M.
        Elimination of perinatal HIV infection in the USA and other high-income countries: achievements and challenges.
        Curr Opin HIV AIDS. 2013; 8: 447-456
        • Patel P.
        • Borkowf C.B.
        • Brooks J.T.
        • Lasry A.
        • Lansky A.
        • Mermin J.
        Estimating per-act HIV transmission risk: a systematic review.
        AIDS. 2014; 28: 1509-1519
        • Mugo N.R.
        • Hong T.
        • Celum C.
        • et al.
        Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
        JAMA. 2014; 312: 362-371
        • Callahan R.
        • Nanda K.
        • Kapiga S.
        • et al.
        Pregnancy and contraceptive use among women participating in the FEM-PrEP trial.
        J Acquir Immune Defic Syndr. 2015; 68: 196-203
        • Antiretroviral Pregnancy Registry Steering Committee
        Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989–31 July 2015.
        Registry Coordinating Center, Wilmington (NC)2015 (Available at:)
        • Siberry G.K.
        • Williams P.L.
        • Mendez H.
        • et al.
        Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.
        AIDS. 2012; 26: 1151-1159
        • Gibb D.M.
        • Kizito H.
        • Russell E.C.
        • et al.
        Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
        PLoS Med. 2012; 9: e1001217
      3. Siberry GK, Tierney C, Stranix-Chibanda L, et al. Impact of maternal tenofovir use on HIV-exposed newborn bone mineral content. Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb 22-5, 2016.

        • Ransom C.E.
        • Huo Y.
        • Patel K.
        • et al.
        Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.
        J Acquir Immune Defic Syndr. 2013; 64: 374-381
        • Himes S.K.
        • Wu J.W.
        • Jacobson D.L.
        • et al.
        Meconium tenofovir concentrations and growth and bone outcomes in prenatally tenofovir exposed HIV-uninfected children.
        Pediatr Infect Dis J. 2015; 34: 851-857
      4. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed February 1, 2016.

        • Terrault N.A.
        • Bzowej N.H.
        • Chang K.M.
        • Hwang J.P.
        • Jonas M.M.
        • Murad M.H.
        AASLD guidelines for treatment of chronic hepatitis B.
        Hepatology. 2016; 63: 261-283
        • Ehrhardt S.
        • Xie C.
        • Guo N.
        • Nelson K.
        • Thio C.L.
        Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence.
        Clin Infect Dis. 2015; 60: 275-278
        • American College of Obstetricians and Gynecologists
        Committee on Gynecologic Practice: preexposure prophylaxis for the prevention of human immunodeficiency virus. Committee Opinion, no.: 595.
        Obstet Gynecol. 2014; 123: 1133-1136
        • Smith D.K.
        • Grohskopf L.A.
        • Black R.J.
        • et al.
        Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services.
        MMWR Recomm Rep. 2005; 54: 1-20
        • Seidman D.
        • Weber S.
        Integrating preexposure prophylaxis for human immunodeficiency virus prevention into women’s healthcare in the United States.
        Obstet Gynecol. 2016; 128: 37-43
        • Heffron R.
        • Pintye J.
        • Matthews L.T.
        • Weber S.
        • Mugo N.
        PrEP as peri-conception HIV prevention for women and men.
        Curr HIV/AIDS Rep. 2016; 13: 131-139
        • Chen Y.H.
        • Raymond H.F.
        • McFarland W.
        • Truong H.M.
        HIV risk behaviors in heterosexual partnerships: female knowledge and male behavior.
        AIDS Behav. 2010; 14: 87-91
        • Peterman T.A.
        • Newman D.R.
        • Maddox L.
        • Schmitt K.
        • Shiver S.
        Risk for HIV following a diagnosis of syphilis, gonorrhoea or chlamydia: 328,456 women in Florida, 2000-2011.
        Int J STD AIDS. 2015; 26: 113-119